For a study, researchers stated that Patient-reported outcome (PRO) measures have been increasingly implemented in routine care to aid in clinical decision-making. However, the prognostic value of PRO measures as a tool for decision-making is not easily interpreted by clinicians. The aim of this study was to explore the prognostic value of PRO measures at disease progression and the changes in PRO measures between treatment start (baseline) and disease progression.
Since 2014, patients with lung cancer have completed an electronic version of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaires C30 and LC-13 before every outpatient visit at the Department of Oncology, Denmark. The patients’ responses were used in routine care. Patients receiving palliative antineoplastic treatment were eligible for analysis if the questionnaire had been completed at the initiation of first-line treatment and at disease progression. The prognostic value of the scores was evaluated using a Cox proportional hazard model. A P value (< .01) was considered statistically significant. A total of 94 screened patients were included.
At disease progression, survival could be predicted from the absolute score of the global health scale, 3 functional scales (emotional, role, physical), and 7 symptom scales (chest pain, lung cancer dyspnea, hemoptysis, dyspnea, pain, fatigue). In addition, changes in chest pain, dyspnea, dysphagia, hemoptysis predicted for survival at progression.
Reference link- www.clinical-lung-cancer.com/article/S1525-7304(20)30294-1/fulltext
